Applied BioCode - Public Comps and Valuation Multiples

Applied BioCode Overview

About Applied BioCode

Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.

Founded

2016

HQ

Employees

n/a

Website

apbiocode.com

Sectors

Medical Imaging & Diagnostics
Laboratory Services
HealthTech
FemTech
SexTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$33.4M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Applied BioCode Financials

Applied BioCode has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Applied BioCode achieved revenue of $10.4M and an EBITDA of -$6.0M.

Applied BioCode expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Applied BioCode valuation multiples based on analyst estimates

Applied BioCode P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$11.9M	$10.4M	XXX	XXX	XXX
Gross Profit	$7.1M	$8.1M	XXX	XXX	XXX
Gross Margin	59%	78%	XXX	XXX	XXX
EBITDA	-$3.0M	-$6.0M	XXX	XXX	XXX
EBITDA Margin	-25%	-58%	XXX	XXX	XXX
Net Profit	-$5.6M	-$5.0M	XXX	XXX	XXX
Net Margin	-47%	-48%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Applied BioCode Stock Performance

As of April 15, 2025, Applied BioCode's stock price is TWD 19 (or $1).

Applied BioCode has current market cap of TWD 1.9B (or $58.7M), and EV of TWD 1.1B (or $33.4M).

See Applied BioCode trading valuation data

Applied BioCode Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$33.4M	$58.7M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Applied BioCode Valuation Multiples

As of April 15, 2025, Applied BioCode has market cap of $58.7M and EV of $33.4M.

Applied BioCode's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Applied BioCode's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Applied BioCode and 10K+ public comps

Applied BioCode Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$33.4M	XXX	XXX	XXX
EV/Revenue	3.2x	XXX	XXX	XXX
EV/EBITDA	-5.6x	XXX	XXX	XXX
P/E	-7.4x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	-5.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Applied BioCode Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Applied BioCode Valuation Multiples

Applied BioCode's NTM/LTM revenue growth is n/a

Applied BioCode's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Applied BioCode's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Applied BioCode's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Applied BioCode and other 10K+ public comps

Applied BioCode Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	-13%	XXX	XXX	XXX	XXX
EBITDA Margin	-58%	XXX	XXX	XXX	XXX
EBITDA Growth	101%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	n/a	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	27%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	34%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	79%	XXX	XXX	XXX	XXX
Opex to Revenue	140%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry